Company intelligence
Curaleaf International
Shaping the future of cannabis through research and product excellence
About Curaleaf International
Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis. Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada. Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.
Verified activity
Signals from Curaleaf International
4 published signals
Research & Knowledge
Curaleaf International published a newly published analysis from the UK Medical Cannabis Registry following patients over two years and building on an earlier six-month report on endometriosis, quality of life, sleep, and anxiety.
Reported by Curaleaf International
Presence & Recognition
Curaleaf International participated in the Cannabis Europa 2026 event where Kirsty Martin spoke with Rita Carneiro, Head of Quality and Qualified Person at Curaleaf International, as part of the Science to Supply series.
Reported by Curaleaf International
Products & Services
Curaleaf International launched the Que Medical Inhalation Device (QMID) in the UK, the first CE-certified liquid inhaler developed for cannabis-based medicines.
Reported by Curaleaf International
Customers & Market
Curaleaf International launched the Que Medical Inhalation Device (QMID) in the UK, the first CE-certified liquid inhaler developed for cannabis-based medicines, and it is now available to prescribers in six countries and counting.
Reported by Curaleaf International